Amarantus BioScience Competitors

Amarantus BioScience (OTCMKTS:AMBS) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Amarantus BioScience and Intec Pharma's revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Amarantus BioScience and Intec Pharma, as reported by MarketBeat.com.

Intec Pharma has a consensus target price of $13.00, indicating a potential upside of 251.35%. Given Intec Pharma's higher possible upside, analysts plainly believe Intec Pharma is more favorable than Amarantus BioScience.

Profitability

This table compares Amarantus BioScience and Intec Pharma's net margins, return on equity and return on assets.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Comparatively, 3.3% of Intec Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amarantus BioScience beats Intec Pharma on 4 of the 6 factors compared between the two stocks.

Novelion Therapeutics (OTCMKTS:NVLNF) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Novelion Therapeutics and Amarantus BioScience, as provided by MarketBeat.

Institutional & Insider Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Amarantus BioScience shares are held by institutional investors. 3.6% of Novelion Therapeutics shares are held by company insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Novelion Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Profitability

This table compares Novelion Therapeutics and Amarantus BioScience's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Novelion Therapeutics and Amarantus BioScience's top-line revenue, earnings per share and valuation.

Amarantus BioScience has lower revenue, but higher earnings than Novelion Therapeutics.

Summary

Novelion Therapeutics beats Amarantus BioScience on 3 of the 4 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and Nuvo Pharmaceuticals (OTCMKTS:NRIFF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Amarantus BioScience and Nuvo Pharmaceuticals, as provided by MarketBeat.com.

Volatility and Risk

Amarantus BioScience has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Nuvo Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amarantus BioScience and Nuvo Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Amarantus BioScience and Nuvo Pharmaceuticals' gross revenue, earnings per share and valuation.

Nuvo Pharmaceuticals has higher revenue and earnings than Amarantus BioScience.

Summary

Nuvo Pharmaceuticals beats Amarantus BioScience on 4 of the 7 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Medicure and Amarantus BioScience, as provided by MarketBeat.

Institutional and Insider Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 12.9% of Medicure shares are held by insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Medicure has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Medicure and Amarantus BioScience's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Medicure and Amarantus BioScience's top-line revenue, earnings per share (EPS) and valuation.

Amarantus BioScience has lower revenue, but higher earnings than Medicure.

Summary

Amarantus BioScience beats Medicure on 5 of the 7 factors compared between the two stocks.

CannaPharmaRX (OTCMKTS:CPMD) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares CannaPharmaRX and Amarantus BioScience's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for CannaPharmaRX and Amarantus BioScience, as reported by MarketBeat.

Valuation and Earnings

This table compares CannaPharmaRX and Amarantus BioScience's revenue, earnings per share and valuation.

Institutional and Insider Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 71.9% of CannaPharmaRX shares are owned by insiders. Comparatively, 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Summary

Amarantus BioScience beats CannaPharmaRX on 3 of the 5 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amarantus BioScience and CannaPharmaRX, as reported by MarketBeat.com.

Institutional & Insider Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 10.3% of Amarantus BioScience shares are held by company insiders. Comparatively, 71.9% of CannaPharmaRX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Amarantus BioScience and CannaPharmaRX's net margins, return on equity and return on assets.

Risk and Volatility

Amarantus BioScience has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amarantus BioScience and CannaPharmaRX's revenue, earnings per share and valuation.

Summary

Amarantus BioScience beats CannaPharmaRX on 3 of the 5 factors compared between the two stocks.